, Graphique 10.1. Adultes nés à l'étranger et nés dans le pays qui déclarent avoir un bon état de santé général, ne pas être limités dans leurs activités par des problèmes de santé et ne pas souffrir de maladies chroniques, 2012

F. Inca--les-cancers-en,

G. Curigliano, H. J. Burstein, E. P. Winer, M. Gnant, P. Dubsky et al., Deescalating and escalating treatments for early-stage breast cancer: the St, Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer, vol.01, pp.1700-1712, 2017.

B. Fisher, N. H. Slack, P. J. Cavanaugh, B. Gardner, and R. G. Ravdin, Postoperative Radiotherapy in the Treatment of Breast Cancer, Annals of Surgery, vol.172, issue.4, pp.711-732, 1970.

. Ebctcg), R. Peto, C. Davies, J. Godwin, R. Gray et al., Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials, The Lancet, vol.379, issue.9814, pp.432-444, 2012.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.

J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer, Journal of Clinical Oncology, vol.17, issue.5, pp.1474-1474, 1999.

, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, The Lancet, vol.365, issue.9472, pp.1687-1717, 2005.

J. L. Blum, P. J. Flynn, G. Yothers, L. Asmar, C. E. Geyer et al., Anthracyclines in Early Breast Cancer: The ABC Trials?USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology), Journal of Clinical Oncology, vol.35, issue.23, pp.2647-2655, 2017.

A. De-roquancourt, Critères anatomopathologiques de décision dans les cancers du sein à un stade précoce, Diagnostic et décision dans le cancer du sein à un stade précoce, pp.51-56, 2012.

H. Autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

D. Sur,

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, New England Journal of Medicine, vol.351, issue.27, pp.2817-2826, 2004.

S. Paik, G. Tang, S. Shak, C. Kim, J. Baker et al., Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor?Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3734, 2006.

I. Krop, N. Ismaila, F. Andre, R. C. Bast, W. Barlow et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update, Journal of Clinical Oncology, vol.35, issue.24, pp.2838-2847, 2017.

T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001.

F. Fitzal, M. Filipits, M. Rudas, R. Greil, O. Dietze et al., The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial, British Journal of Cancer, vol.112, issue.8, pp.1405-1410, 2015.

M. Dowsett, J. Cuzick, C. Wale, J. Forbes, E. A. Mallon et al., Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study, Journal of Clinical Oncology, vol.28, issue.11, pp.1829-1834, 2010.

D. Vorobiof, Faculty Opinions recommendation of Prospective Validation of a 21-Gene Expression Assay in Breast Cancer., 2016.

,

F. Cardoso, L. J. Van?t-veer, J. Bogaerts, L. Slaets, G. Viale et al., 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, New England Journal of Medicine, vol.375, issue.8, pp.717-729, 2016.

,

J. Gligorov, X. B. Pivot, W. Jacot, H. L. Naman, D. Spaeth et al., Prospective Clinical Utility Study of the Use of the 21?Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor?Positive Early Invasive Breast Cancer: Results From the SWITCH Study, The Oncologist, vol.20, issue.8, pp.873-879, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02316338

R. Yerushalmi, R. Woods, P. M. Ravdin, M. M. Hayes, and K. A. Gelmon, Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, pp.174-183, 2010.

G. Viale, A. Giobbie-hurder, M. M. Regan, A. S. Coates, M. G. Mastropasqua et al., Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole, Journal of Clinical Oncology, vol.26, issue.34, pp.5569-5575, 2008.

F. Penault-llorca, F. André, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor?Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2809-2815, 2009.

F. Penault-llorca, F. André, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor?Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2809-2815, 2009.

M. Polley, S. C. Leung, L. M. Mcshane, D. Gao, J. C. Hugh et al., An International Ki67 Reproducibility Study, JNCI: Journal of the National Cancer Institute, vol.105, issue.24, pp.1897-1906, 2013.

A. S. Coates, E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant et al., Tailoring therapies--improving the management of early breast cancer, St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, vol.26, pp.1533-1579, 2015.

B. Ejlertsen, Multicentre Cancer Chemotherapy Group Randomised Trial of Adjuvant Chemotherapy for 'Early' Breast Cancer, Dan Med J. mai, vol.63, issue.5, 2013.

E. Chéreau, C. Coutant, J. Gligorov, B. Lesieur, M. Antoine et al., Discordance With Local Guidelines for Adjuvant Chemotherapy in Breast Cancer: Reasons and Effect on Survival, Clinical Breast Cancer, vol.11, issue.1, pp.46-51, 2011.

D. Zarca, Cancers du sein et signatures moléculaires : ici et maintenant, Gynécologie Obstétrique & Fertilité, vol.40, issue.10, pp.557-560, 2012.

D. Sur, Graphique 1.1. Croissance annuelle moyenne en pourcentage sur la période 1995-2009 ou dernière période disponible

M. Gnant, M. Filipits, R. Greil, H. Stoeger, M. Rudas et al., Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone, Annals of Oncology, vol.25, issue.2, pp.339-345, 2014.

J. Hornberger, M. D. Alvarado, C. Rebecca, H. R. Gutierrez, T. M. Yu et al., Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review, JNCI Journal of the National Cancer Institute, vol.104, issue.14, pp.1068-1079, 2012.

J. Hornberger, M. D. Alvarado, C. Rebecca, H. R. Gutierrez, T. M. Yu et al., Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review, JNCI Journal of the National Cancer Institute, vol.104, issue.14, pp.1068-1079, 2012.

M. C. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung et al., Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.101, issue.10, pp.736-750, 2009.

M. C. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung et al., Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.101, issue.10, pp.736-750, 2009.

A. Prat, M. C. Cheang, M. Martín, J. S. Parker, E. Carrasco et al., Prognostic Significance of Progesterone Receptor?Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer, Journal of Clinical Oncology, vol.31, issue.2, pp.203-209, 2013.

O. Gluz, U. A. Nitz, M. Christgen, R. E. Kates, S. Shak et al., West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment, Journal of Clinical Oncology, vol.34, issue.20, pp.2341-2349, 2016.

, Gene Expression?Guided Adjuvant Chemotherapy in Breast Cancer, New England Journal of Medicine, vol.379, issue.17, pp.1680-1682, 2018.

S. D. Ramsey, W. E. Barlow, A. M. Gonzalez-angulo, S. Tunis, L. Baker et al., Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes, Contemporary Clinical Trials, vol.34, issue.1, pp.1-9, 2013.

R. M. Simon, S. Paik, and D. F. Hayes, Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, pp.1446-1452, 2009.

M. J. Duffy, N. Harbeck, M. Nap, R. Molina, A. Nicolini et al., Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM), European Journal of Cancer, vol.75, pp.284-298, 2017.

F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.30, issue.10, p.1674, 2019.

N. Harbeck, K. Sotlar, R. Wuerstlein, and S. Doisneau-sixou, Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow, Cancer Treatment Reviews, vol.40, issue.3, pp.434-444, 2014.

U. Wazir and K. Mokbel, Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine, World Journal of Clinical Oncology, vol.5, issue.5, p.795, 2014.

D. Hequet, C. Callens, D. Gentien, B. Albaud, M. Mouret-reynier et al.,

. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers, PloS One, vol.12, issue.10, p.185753, 2017.

K. Mokbel, U. Wazir, A. Wazir, A. Kasem, and K. Mokbel, The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2? Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index, Anticancer Research, vol.38, issue.8, pp.4747-4752, 2018.

J. Gligorov, F. Penault-llorca, M. Aapro, L. Aimard, P. Alfonsi et al., Recommandations pour la pratique clinique: Nice-Saint-Paul-de-Vence 2009 cancers du sein « et soins de support », Oncologie, vol.11, issue.11, pp.497-505, 2009.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.5, pp.v8-v30, 2015.

M. S. Copur, R. Ramaekers, D. Gauchan, M. Norvell, and D. Clark, Recent ASCO Guideline on the Use of Biomarkers for Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer, Journal of Clinical Oncology, vol.34, issue.32, pp.3943-3944, 2016.

A. Disponible-sur-;-cariou, R. Rouzier, S. Baffert, A. Soilly, and D. Hequet, Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study, PloS One, vol.13, issue.8, p.202385, 2018.

O. Wang, Application of numerical interval analysis for statistical computing in a massively parallel computing environment

F. Cardoso, L. J. Van?t-veer, J. Bogaerts, L. Slaets, G. Viale et al., 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, New England Journal of Medicine, vol.375, issue.8, pp.717-729, 2016.

F. Penault-llorca, F. Kwiatkowski, A. Arnaud, C. Levy, M. Leheurteur et al., Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2?14), The Breast, vol.49, pp.132-140, 2020.

H. O. Ohnstad, E. Borgen, R. S. Falk, T. G. Lien, M. Aaserud et al., Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up, Breast Cancer Research, vol.19, issue.1, p.120, 2017.